

inflammatory response, apoptosis of eosinophils can be inhibited through the activity of survival-promoting cytokines such as IL-3 and GM-CSF. However, an increase of activated eosinophils that are not rapidly removed by apoptosis can result in the release of eosinophil granule proteins at already inflamed sites which can damage tissue and cause inflammation to be further exacerbated. Several diseases have been shown to be linked to eosinophil activation such as Churg Strauss syndrome, rheumatoid arthritis, and allergic asthma (Wechsler et al., *J Allergy Clin Immunol.*, 2012, 130(3):563-71). There is currently a need for therapies that can control the activity of immune cells involved in inflammation, such as the activity of eosinophils and mast cells.

[0006] Previous studies have demonstrated that eosinophils undergo apoptosis when Siglec-8 is crosslinked with specific murine antibodies raised against the extracellular portion of Siglec-8 (Nutku et al., *Blood*, 2003, 336:918-24). These antibodies are described in U.S. Pat. No. 8,207,305, U.S. Pat. No. 8,197,811, U.S. Pat. No. 7,871,612, and U.S. Pat. No. 7,557,191. Humanized anti-Siglec-8 antibodies are described in U.S. Pat. No. 9,546,215.

[0007] Antibodies that bind to human Siglec-8 are under clinical testing in healthy volunteers and patients with indolent systemic mastocytosis (ISM), chronic urticarial, and allergic conjunctivitis. To date, anti-Siglec-8 antibody treatment has been well tolerated, with the most commonly observed adverse event being infusion-related reactions (IRRs). While most IRRs have been mild to moderate, there remains a need for methods that improve anti-Siglec-8 antibody treatments, *e.g.*, by preventing and/or lessening the severity of IRRs.

[0008] All references cited herein, including patent applications, patent publications, and scientific literature, are herein incorporated by reference in their entirety, as if each individual reference were specifically and individually indicated to be incorporated by reference.

BRIEF SUMMARY

[0009] To meet this and other needs, the present disclosure relates, *inter alia*, to methods of administering a composition comprising an antibody that binds to human Siglec-8.

[0010] Accordingly, certain **aspectexamples** of the present disclosure relate to methods for administering a composition comprising an antibody that binds to human Siglec-8 to an individual in need thereof. In some **embodimentexamples**, the methods comprise administering a corticosteroid to the individual; and at least 6 hours after administering the corticosteroid, administering to the individual a first dose of the composition comprising the antibody that binds to human Siglec-8. In some **embodimentexamples**, the methods comprise administering to the individual

a first dose of the composition comprising the antibody that binds to human Siglec-8, wherein a corticosteroid is administered to the individual at least 6 hours prior to administration of the first dose. In some [embodimentexamples](#), the methods comprise administering to the individual a first dose of the composition, wherein the first dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours. In some [embodimentexamples](#), a corticosteroid is administered to the individual at least 6 hours prior to administration of the first dose. In some [embodimentexamples](#), the individual is a human.

[0010a] In one aspect, the present disclosure refers to use of a composition comprising an antibody that binds to human Siglec-8 in the manufacture of a medicament for administration to an individual in need thereof, wherein a corticosteroid is to be administered to the individual at least 6 hours prior to administration of a first dose of the composition.

[0010b] In one aspect, the present disclosure refers to use of a composition comprising an antibody that binds to human Siglec-8 in the manufacture of a medicament for administration to an individual in need thereof, wherein a first dose of the composition is to be administered to the individual by intravenous infusion over a period of about 4 hours; wherein optionally a corticosteroid is to be administered to the individual at least 6 hours prior to administration of the first dose of the composition.

[0011] In some [embodimentexamples](#), the corticosteroid is administered to the individual at least 12 hours prior to administration of the first dose. In some [embodimentexamples](#), the corticosteroid is administered to the individual within 24 hours prior to administration of the first dose. In some [embodimentexamples](#), the corticosteroid is administered to the individual 12-24 hours prior to administration of the first dose. In some [embodimentexamples](#), the corticosteroid is prednisone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, or prednisolone. In some [embodimentexamples](#), greater than 0.5mg/kg prednisone is administered to the individual at least 6 hours (and optionally within 24 hours), at least 12 hours (and optionally within 24 hours), or 12-24 hours prior to administration of the first dose. In some [embodimentexamples](#), 0.5mg/kg to 1mg/kg prednisone is administered to the individual at least 6 hours (and optionally within 24 hours), at least 12 hours (and optionally within 24 hours), or 12-24 hours prior to administration of the first dose. In some [embodimentexamples](#), 1mg/kg prednisone is administered to the individual at least 6 hours (and optionally within 24 hours), at least 12 hours (and optionally within 24 hours), or 12-24 hours prior to administration of the first dose. In some [embodimentexamples](#), 80mg prednisone is administered to the individual at least 6 hours (and optionally within 24 hours), at least 12 hours (and optionally within 24 hours), or 12-24 hours prior to administration of the first dose. In some [embodimentexamples](#), 60mg prednisone is administered to the individual at least 6 hours (and optionally within 24 hours), at least 12 hours (and optionally within 24 hours), or 12-24 hours prior to administration of the first dose. In some [embodimentexamples](#), the corticosteroid is self-administered by the individual. In some [embodimentexamples](#), the corticosteroid is administered orally to the individual. In some [embodimentexamples](#), administration of the corticosteroid at least 6 hours prior to administration of the first dose reduces the risk and/or severity of infusion-related reaction (IRR) in the individual, as compared to administration of the first dose without administration of the corticosteroid at least 6 hours prior. In some [embodimentexamples](#), administration of the corticosteroid at least 12 hours prior to administration of the first dose reduces the risk

and/or severity of infusion-related reaction (IRR) in the individual, as compared to administration of the first dose without administration of the corticosteroid at least 12 hours prior. In some [embodimentexamples](#), administration of the corticosteroid 12-24 hours prior to administration of the first dose reduces the risk and/or severity of infusion-related reaction (IRR) in the individual, as compared to administration of the first dose without administration of the corticosteroid 12-24 hours prior.

[0012] In some [embodimentexamples](#) according to any of the [embodimentexamples](#) described herein, the antibody that binds to human Siglec-8 is administered to the individual at between 0.1mg/kg and 10mg/kg in the first dose. In some [embodimentexamples](#), the antibody that binds to human Siglec-8 is administered to the individual at between about 1mg/kg and about 3mg/kg in the first dose. In some [embodimentexamples](#), the antibody that binds to human Siglec-8 is administered to the individual at 1mg/kg or 3mg/kg in the first dose. In some [embodimentexamples](#), the first dose of the composition is administered intravenously to the individual. In some [embodimentexamples](#), the first dose of the composition is administered subcutaneously to the individual.

[0013] In some [embodimentexamples](#), the first dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours. In some [embodimentexamples](#), less than 50% of total volume of the first dose is administered to the individual in the first 2 hours of the infusion. In some [embodimentexamples](#), less than 30% of total volume of the first dose is administered to the individual in the first 2 hours of the infusion. In some [embodimentexamples](#), the first dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 1 mL/hour for 15 minutes, 5 mL/hour for 15 minutes, 10 mL/hour for 30 minutes, 15 mL/hour for 30 minutes, 25 mL/hour for 30 minutes, 30 mL/hour for 30 minutes, 35 mL/hour for 30 minutes, and 40 mL/hour for 62 minutes. In some [embodimentexamples](#), administration of the first dose of the composition by intravenous infusion over a period of about 4 hours reduces the risk of infusion-related reaction (IRR) in the individual, as compared to administration of the first dose by intravenous infusion over a period that is less than about 4 hours. In some [embodimentexamples](#), administration of the first dose of the composition by intravenous infusion over a period of about 4 hours reduces the severity of infusion-related reaction (IRR) in the individual, as compared to administration of the first dose by intravenous infusion over a period that is less than about 4 hours.

[0014] In some [embodimentexamples](#) according to any of the [embodimentexamples](#) described herein, the methods further comprise administering a corticosteroid to the individual 1-2 hours prior to

administration of the first dose. In some [embodimentexamples](#), the corticosteroid administered to the individual 1-2 hours prior to administration of the first dose is prednisone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, or prednisolone. In some [embodimentexamples](#), greater than 0.5mg/kg prednisone is administered to the individual 1-2 hours prior to administration of the first dose. In some [embodimentexamples](#), 0.5mg/kg to 1mg/kg prednisone is administered to the individual 1-2 hours prior to administration of the first dose. In some [embodimentexamples](#), greater than 1mg/kg prednisone is administered to the individual 1-2 hours prior to administration of the first dose. In some [embodimentexamples](#), 60mg or 80mg prednisone is administered to the individual 1-2 hours prior to administration of the first dose. In some [embodimentexamples](#), the corticosteroid is administered orally to the individual. In some [embodimentexamples](#), the corticosteroid administered to the individual 1-2 hours prior to administration of the first dose is methylprednisolone. In some [embodimentexamples](#), 100mg methylprednisolone is administered to the individual 1-2 hours prior to administration of the first dose. In some [embodimentexamples](#), the corticosteroid is administered intravenously to the individual. In some [embodimentexamples](#), the methods further comprise administering an antihistamine to the individual 1-2 hours prior to administration of the first dose. In some [embodimentexamples](#), the antihistamine is cetirizine. In some [embodimentexamples](#), 10mg cetirizine is administered to the individual 1-2 hours prior to administration of the first dose. In some [embodimentexamples](#), 10mg cetirizine is administered to the individual no less than 40 minutes and no more than 180 minutes prior to administration of the first dose. In some [embodimentexamples](#), 10mg cetirizine is administered to the individual 40 minutes to 180 minutes prior to administration of the first dose (e.g., inclusive of 40 minutes and 180 minutes). In some [embodimentexamples](#), the antihistamine is administered orally to the individual. In some [embodimentexamples](#), the methods further comprise administering an antipyretic or non-steroidal anti-inflammatory drug (NSAID) to the individual 1-2 hours prior to administration of the first dose. In some [embodimentexamples](#), the antipyretic is acetaminophen. In some [embodimentexamples](#), 975-1000mg acetaminophen is administered to the individual 1-2 hours prior to administration of the first dose. In some [embodimentexamples](#), 975-1000mg acetaminophen is administered to the individual no less than 40 minutes and no more than 180 minutes prior to administration of the first dose. In some [embodimentexamples](#), the antipyretic or NSAID is administered orally to the individual.

[0015] In some [embodimentexamples](#) according to any of the [embodimentexamples](#) described herein, the methods further comprise administering to the individual a second dose of a composition comprising an antibody that binds to human Siglec-8. In some [embodimentexamples](#), the second dose is

administered to the individual about 28 days after the first dose. In some [embodimentexamples](#), the second dose is administered to the individual about 4 weeks after the first dose. In some [embodimentexamples](#), the second dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours. In some [embodimentexamples](#), less than 50% of total volume of the second dose is administered to the individual in the first 2 hours of the infusion. In some [embodimentexamples](#), less than 30% of total volume of the second dose is administered to the individual in the first 2 hours of the infusion. In some [embodimentexamples](#), the second dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 1 mL/hour for 15 minutes, 5 mL/hour for 15 minutes, 10 mL/hour for 30 minutes, 15 mL/hour for 30 minutes, 25 mL/hour for 30 minutes, 30 mL/hour for 30 minutes, 35 mL/hour for 30 minutes, and 40 mL/hour for 62 minutes. In some [embodimentexamples](#), the second dose is administered to the individual without administration of a corticosteroid to the individual at least 6 hours, at least 12 hours, 6-24 hours, or 12-24 hours prior to administration of the second dose. In some [embodimentexamples](#), a corticosteroid is administered to the individual 1-2 hours, at least 6 hours, at least 12 hours, 6-24 hours, or 12-24 hours prior to administration of the second dose. In some [embodimentexamples](#), a corticosteroid is administered to the individual at least 6 hours, at least 12 hours, 6-24 hours, or 12-24 hours prior to administration of the second dose. In some [embodimentexamples](#), the corticosteroid is prednisone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, or prednisolone. In some [embodimentexamples](#), greater than 0.5mg/kg prednisone is administered to the individual at least 6 hours (and optionally within 24 hours), at least 12 hours (and optionally within 24 hours), or 12-24 hours prior to administration of the second dose. In some [embodimentexamples](#), 1mg/kg prednisone is administered to the individual at least 6 hours (and optionally within 24 hours), at least 12 hours (and optionally within 24 hours), or 12-24 hours prior to administration of the second dose. In some [embodimentexamples](#), 80mg prednisone is administered to the individual at least 6 hours (and optionally within 24 hours), at least 12 hours (and optionally within 24 hours), or 12-24 hours prior to administration of the second dose. In some [embodimentexamples](#), the corticosteroid is self-administered by the individual. In some [embodimentexamples](#), the corticosteroid is administered orally to the individual. In some [embodimentexamples](#), the antibody that binds to human Siglec-8 is administered to the individual at between 0.1mg/kg and 10mg/kg in the second dose. In some [embodimentexamples](#), the antibody that binds to human Siglec-8 is administered to the individual at between about 1mg/kg and about 3mg/kg in the second dose. In some [embodimentexamples](#), the

antibody that binds to human Siglec-8 is administered to the individual at 1mg/kg or 3mg/kg in the second dose. In some [embodimentexamples](#), the antibody that binds to human Siglec-8 is administered to the individual at 1mg/kg in the first dose and at 3mg/kg in the second dose. In some [embodimentexamples](#), the antibody that binds to human Siglec-8 is administered to the individual at 3mg/kg in the first dose and at 10mg/kg in the second dose. In some [embodimentexamples](#), the second dose of the composition is administered intravenously to the individual. In some [embodimentexamples](#), the second dose of the composition is administered subcutaneously to the individual. In some [embodimentexamples](#), the methods further comprise administering a corticosteroid to the individual 1-2 hours prior to administration of the second dose. In some [embodimentexamples](#), the corticosteroid administered to the individual 1-2 hours prior to administration of the second dose is methylprednisolone. In some [embodimentexamples](#), 100mg methylprednisolone is administered to the individual 1-2 hours prior to administration of the second dose. In some [embodimentexamples](#), the methods further comprise administering an antihistamine to the individual 1-2 hours prior to administration of the second dose. In some [embodimentexamples](#), 10mg cetirizine is administered to the individual 1-2 hours prior to administration of the second dose. In some [embodimentexamples](#), the antihistamine is administered orally to the individual. In some [embodimentexamples](#), the methods further comprise administering an antipyretic or non-steroidal anti-inflammatory drug (NSAID) to the individual 1-2 hours prior to administration of the second dose. In some [embodimentexamples](#), the antipyretic is acetaminophen. In some [embodimentexamples](#), 975-1000mg acetaminophen is administered to the individual 1-2 hours prior to administration of the second dose. In some [embodimentexamples](#), the antipyretic or NSAID is administered orally to the individual.

[0016] In some [embodimentexamples](#) according to any of the [embodimentexamples](#) described herein, the methods further comprise administering to the individual a third dose of a composition comprising an antibody that binds to human Siglec-8. In some [embodimentexamples](#), the third dose is administered to the individual about 28 days after the second dose. In some [embodimentexamples](#), the third dose is administered to the individual about 4 weeks after the second dose. In some [embodimentexamples](#), the third dose is administered to the individual about 56 days after the first dose. In some [embodimentexamples](#), the third dose is administered to the individual about 8 weeks after the first dose. In some [embodimentexamples](#), the third dose of the composition is administered to the individual by intravenous infusion over a period of about 2 hours to about 4 hours. In some [embodimentexamples](#), the third dose of the composition is administered to the individual by intravenous infusion over a period of about 1 hour to about 4 hours. In some [embodimentexamples](#), the third dose of

the composition is administered to the individual by intravenous infusion over a period of about 2 hours. In some [embodimentexamples](#), the third dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 10 mL/hour for 30 minutes, 25 mL/hour for 15 minutes, 40 mL/hour for 15 minutes, 55 mL/hour for 15 minutes, 70 mL/hour for 15 minutes, 85 mL/hour for 15 minutes, and 100 mL/hour for 16 minutes. In some [embodimentexamples](#), the third dose of the composition is administered to the individual by intravenous infusion over a period of about 3 hours. In some [embodimentexamples](#), the third dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 2 mL/hour for 30 minutes, 10 mL/hour for 30 minutes, 20 mL/hour for 30 minutes, 40 mL/hour for 30 minutes, and 60 mL/hour for 64 minutes. In some [embodimentexamples](#), the third dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours. In some [embodimentexamples](#), the third dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 1 mL/hour for 15 minutes, 5 mL/hour for 15 minutes, 10 mL/hour for 30 minutes, 15 mL/hour for 30 minutes, 25 mL/hour for 30 minutes, 30 mL/hour for 30 minutes, 35 mL/hour for 30 minutes, and 40 mL/hour for 62 minutes. In some [embodimentexamples](#), the third dose of the composition is administered to the individual by intravenous infusion over a period of about 1 hour. In some [embodimentexamples](#), the third dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 24 mL/hour for 15 minutes, and 125.3 mL/hour for 45 minutes. In some [embodimentexamples](#), the third dose is administered to the individual without administration of a corticosteroid to the individual at least 6 hours, at least 12 hours, 6-24 hours, or 12-24 hours prior to administration of the third dose. In some [embodimentexamples](#), a corticosteroid is administered to the individual 1-2 hours, at least 6 hours, at least 12 hours, 6-24 hours, or 12-24 hours prior to administration of the third dose. In some [embodimentexamples](#), the methods comprise: administering to the individual a first dose of the composition on Day 1, wherein the first dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours (optionally wherein a corticosteroid is administered to the individual at least 6 hours prior to administration of the first dose); administering to the individual a second dose of the composition on Day 29 (± 3 days), wherein the second dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours; and administering to the individual a third dose of the composition on Day 57 (± 3 days), wherein the third dose of the composition is administered to the individual by intravenous

infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (e.g., as described herein). In some [embodimentexamples](#), the methods comprise: administering to the individual a first dose of the composition on Week 1, wherein the first dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours (optionally wherein a corticosteroid is administered to the individual at least 6 hours prior to administration of the first dose); administering to the individual a second dose of the composition on Week 4 (± 3 days), wherein the second dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours; and administering to the individual a third dose of the composition on Week 8 (± 3 days), wherein the third dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (e.g., as described herein).

[0017] In some [embodimentexamples](#) according to any of the [embodimentexamples](#) described herein, the methods further comprise administering to the individual a fourth dose of a composition comprising an antibody that binds to human Siglec-8. In some [embodimentexamples](#), the fourth dose is administered to the individual about 28 days after the third dose. In some [embodimentexamples](#), the fourth dose is administered to the individual about 4 weeks after the third dose. In some [embodimentexamples](#), the fourth dose is administered to the individual about 56 days after the second dose. In some [embodimentexamples](#), the fourth dose is administered to the individual about 8 weeks after the second dose. In some [embodimentexamples](#), the fourth dose is administered to the individual about 84 days after the first dose. In some [embodimentexamples](#), the fourth dose is administered to the individual about 12 weeks after the first dose. In some [embodimentexamples](#), the fourth dose of the composition is administered to the individual by intravenous infusion over a period of about 2 hours to about 4 hours. In some [embodimentexamples](#), the fourth dose of the composition is administered to the individual by intravenous infusion over a period of about 1 hour to about 4 hours. In some [embodimentexamples](#), the fourth dose of the composition is administered to the individual by intravenous infusion over a period of about 2 hours. In some [embodimentexamples](#), the fourth dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 10 mL/hour for 30 minutes, 25 mL/hour for 15 minutes, 40 mL/hour for 15 minutes, 55 mL/hour for 15 minutes, 70 mL/hour for 15 minutes, 85 mL/hour for 15 minutes, and 100 mL/hour for 16 minutes. In some [embodimentexamples](#), the fourth dose of the composition is administered to the individual by intravenous infusion over a period of about 3

hours. In some [embodimentexamples](#), the fourth dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 2 mL/hour for 30 minutes, 10 mL/hour for 30 minutes, 20 mL/hour for 30 minutes, 40 mL/hour for 30 minutes, and 60 mL/hour for 64 minutes. In some [embodimentexamples](#), the fourth dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours. In some [embodimentexamples](#), the fourth dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 1 mL/hour for 15 minutes, 5 mL/hour for 15 minutes, 10 mL/hour for 30 minutes, 15 mL/hour for 30 minutes, 25 mL/hour for 30 minutes, 30 mL/hour for 30 minutes, 35 mL/hour for 30 minutes, and 40 mL/hour for 62 minutes. In some [embodimentexamples](#), the fourth dose of the composition is administered to the individual by intravenous infusion over a period of about 1 hour. In some [embodimentexamples](#), the fourth dose is administered to the individual by intravenous infusion according to the following schedule, in chronological order: 24 mL/hour for 15 minutes, and 125.3 mL/hour for 45 minutes. In some [embodimentexamples](#), the methods comprise: administering to the individual a first dose of the composition on Day 1, wherein the first dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours (optionally wherein a corticosteroid is administered to the individual at least 6 hours prior to administration of the first dose); administering to the individual a second dose of the composition on Day 29 (± 3 days), wherein the second dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours; administering to the individual a third dose of the composition on Day 57 (± 3 days), wherein the third dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein); and administering to the individual a fourth dose of the composition on Day 85 (± 3 days), wherein the fourth dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein). In some [embodimentexamples](#), the methods comprise: administering to the individual a first dose of the composition on Week 1, wherein the first dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours (optionally wherein a corticosteroid is administered to the individual at least 6 hours prior to administration of the first dose); administering to the individual a second dose of the composition on Week 4 (± 3 days), wherein the second dose of the composition is administered to the individual by

intravenous infusion over a period of about 4 hours; administering to the individual a third dose of the composition on Week 8 (± 3 days), wherein the third dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein); and administering to the individual a fourth dose of the composition on Week 12 (± 3 days), wherein the fourth dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein). In some **embodiment examples**, the methods comprise: administering to the individual a first dose of the composition on Day 1, wherein the first dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours (optionally wherein a corticosteroid is administered to the individual at least 6 hours prior to administration of the first dose); administering to the individual a second dose of the composition on Day 29 (± 3 days), wherein the second dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours; administering to the individual a third dose of the composition on Day 57 (± 3 days), wherein the third dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein); administering to the individual a fourth dose of the composition on Day 85 (± 3 days), wherein the fourth dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein); administering to the individual a fifth dose of the composition on Day 113 (± 3 days), wherein the fifth dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein); and administering to the individual a sixth dose of the composition on Day 141 (± 3 days), wherein the sixth dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein). In some **embodiment examples**, the methods comprise: administering to the individual a first dose of the composition on Week 1, wherein the first dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours (optionally wherein a corticosteroid is administered to the individual at least 6 hours prior to administration of the first dose); administering to the individual a second

dose of the composition on Week 4 (± 3 days), wherein the second dose of the composition is administered to the individual by intravenous infusion over a period of about 4 hours; administering to the individual a third dose of the composition on Week 8 (± 3 days), wherein the third dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein); administering to the individual a fourth dose of the composition on Week 12 (± 3 days), wherein the fourth dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein); administering to the individual a fifth dose of the composition on Week 16 (± 3 days), wherein the fifth dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein); and administering to the individual a sixth dose of the composition on Week 20 (± 3 days), wherein the sixth dose of the composition is administered to the individual by intravenous infusion over a period of about 1 to about 4 hours, about 2 to about 4 hours, or about any of 1 hour, 2 hours, or 4 hours (*e.g.*, as described herein).

[0018] In some [embodimentexamples](#) according to any of the [embodimentexamples](#) described herein, the individual has or has been diagnosed with a disease or disorder characterized by one or more of: an increase in activated eosinophils, increased activity of mast cells expressing Siglec-8, an increase in eosinophils and/or mast cells, or increased activation of eosinophils and/or mast cells. In some [embodimentexamples](#), the individual has or has been diagnosed with a disease or disorder selected from the group consisting of: chronic rhinosinusitis with concomitant asthma, aspirin-exacerbated respiratory disease, adult onset non-atopic asthma with sinus disease, chronic obstructive pulmonary disease, fibrotic disease, pre-fibrotic disease, advanced systemic mastocytosis, indolent systemic mastocytosis (ISM), inflammatory bowel disease (IBD), eosinophilic esophagitis (EOE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), eosinophilic duodenitis, eosinophilic colitis (EOC), mast cell gastritis or mast cell gastroenteritis, gastritis or gastroenteritis with elevated mast cells, irritable bowel syndrome with elevated mast cells, functional gastrointestinal disease, allergic conjunctivitis, giant papillary conjunctivitis, chronic urticaria, allergic bronchopulmonary aspergillosis (ABPA), allergic asthma, asthma with eosinophil or mast cell phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), celiac disease, gastroparesis, hypereosinophilic syndrome, atopic

dermatitis, anaphylaxis, angioedema, mast cell activation syndrome/disorder, and eosinophilic fasciitis. In some [embodimentexamples](#), a method of the present disclosure is used to treat an individual who has or has been diagnosed with a disease or disorder selected from the group consisting of: chronic rhinosinusitis with concomitant asthma, aspirin-exacerbated respiratory disease, adult onset non-atopic asthma with sinus disease, chronic obstructive pulmonary disease, fibrotic disease, pre-fibrotic disease, advanced systemic mastocytosis, indolent systemic mastocytosis (ISM), inflammatory bowel disease (IBD), eosinophilic esophagitis (EOE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), eosinophilic colitis (EOC), eosinophilic duodenitis, mast cell gastritis or mast cell gastroenteritis, gastritis or gastroenteritis with elevated mast cells, irritable bowel syndrome with elevated mast cells, functional gastrointestinal disease, allergic conjunctivitis, giant papillary conjunctivitis, chronic urticaria, allergic bronchopulmonary aspergillosis (ABPA), allergic asthma, asthma with eosinophil or mast cell phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), celiac disease, gastroparesis, hypereosinophilic syndrome, atopic dermatitis, anaphylaxis, angioedema, mast cell activation syndrome/disorder, and eosinophilic fasciitis. In some [embodimentexamples](#), the individual is a human. In some [embodimentexamples](#), prior to administration of the composition, the individual has failed a prior treatment (*e.g.*, a standard of care treatment) for one or more of the indications described above (*e.g.*, EG, EGE, or EoE). In some [embodimentexamples](#), prior to administration of the composition, the individual has had disease symptoms not adequately controlled by a prior treatment (*e.g.*, a standard of care treatment) for one or more of the indications described above (*e.g.*, EG, EGE, or EoE). Non-limiting examples of prior treatments include proton pump inhibitors (PPIs), systemic or topical corticosteroids, and/or diet, among others.

[0019] In some [embodimentexamples](#) according to any of the [embodimentexamples](#) described herein, the methods result in a decrease in eosinophil count as compared to eosinophil count prior to administration of the composition, *e.g.*, in a biopsy sample obtained from the individual (for tissue eosinophil count) or peripheral blood (for blood eosinophil count). For example, the individual may have EG, EGE, and/or EoE, and the biopsy sample is from the gastric or duodenal mucosa. In some [embodimentexamples](#), the methods result in at least 75%, at least 80%, at least 85%, or at least 90% decrease in tissue eosinophil count, as compared to tissue eosinophil count prior to administration of the composition, *e.g.*, in a biopsy sample (*e.g.*, from the esophagus, gastric mucosa, or duodenal mucosa) obtained from an individual with EG, EGE, and/or EoE. In some [embodimentexamples](#), the methods result in a decrease in one or more symptoms in

the individual, as compared to one or more symptoms in the individual prior to administration of the composition (*e.g.*, one or more of abdominal pain, nausea, diarrhea, vomiting, fullness before finishing a meal, loss of appetite, abdominal cramping, and bloating in an individual with EG, EGE, and/or EoE). In some [embodimentexamples](#), the methods result in a decrease of at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% in severity and/or frequency of one or more symptoms in the individual, as compared to one or more symptoms in the individual prior to administration of the composition (*e.g.*, one or more of abdominal pain, nausea, diarrhea, vomiting, fullness before finishing a meal, loss of appetite, abdominal cramping, and bloating in an individual with EG, EGE, and/or EoE). In some [embodimentexamples](#), the methods result in a response rate of at least 50%, at least 60%, or at least 70%, *e.g.*, in individuals with EG, EGE, and/or EoE. In some [embodimentexamples](#), response rate reflects the percentage of individuals with a reduction in tissue biopsy eosinophil count and/or reduction in symptoms, as compared to prior to administration of the composition. In some [embodimentexamples](#), the methods result in a decrease of at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% in severity of dysphagia in the individual, as compared to severity of dysphagia in the individual prior to administration of the composition (*e.g.*, in an individual with EG, EGE, and/or EoE).

[0020] In some [embodimentexamples](#) according to any of the [embodimentexamples](#) described herein, the antibody comprises a Fc region and N-glycoside-linked carbohydrate chains linked to the Fc region, wherein less than 50% of the N-glycoside-linked carbohydrate chains of the antibody in the composition contain a fucose residue. In some [embodimentexamples](#), substantially none of the N-glycoside-linked carbohydrate chains of the antibody in the composition contain a fucose residue. In some [embodimentexamples](#), the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and/or wherein the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:66. In some [embodimentexamples](#), the antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises (i) HVR-H1 comprising the

amino acid sequence of SEQ ID NO:61, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:62, and (iii) HVR-H3 comprising the amino acid sequence selected from SEQ ID NOs:67-70; and/or wherein the light chain variable region comprises (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:64, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:65, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:71. In some [embodimentexamples](#), the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:6; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NO:16 or 21. In some [embodimentexamples](#), the antibody comprises a heavy chain variable region comprising the amino acid sequence selected from SEQ ID NOs:11-14; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NOs:23-24. In some [embodimentexamples](#), the antibody comprises a heavy chain variable region comprising the amino acid sequence selected from SEQ ID NOs:2-14; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NOs:16-24. In some [embodimentexamples](#), the antibody comprises a heavy chain variable region comprising the amino acid sequence selected from SEQ ID NOs:2-10; and/or a light chain variable region comprising the amino acid sequence selected from SEQ ID NOs:16-22. In some [embodimentexamples](#), the antibody comprises: (a) heavy chain variable region comprising: (1) an HC-FR1 comprising the amino acid sequence selected from SEQ ID NOs:26-29; (2) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61; (3) an HC-FR2 comprising the amino acid sequence selected from SEQ ID NOs:31-36; (4) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62; (5) an HC-FR3 comprising the amino acid sequence selected from SEQ ID NOs:38-43; (6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and (7) an HC-FR4 comprising the amino acid sequence selected from SEQ ID NOs:45-46, and/or (b) a light chain variable region comprising: (1) an LC-FR1 comprising the amino acid sequence selected from SEQ ID NOs:48-49; (2) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64; (3) an LC-FR2 comprising the amino acid sequence selected from SEQ ID NOs:51-53; (4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65; (5) an LC-FR3 comprising the amino acid sequence selected from SEQ ID NOs:55-58; (6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66; and (7) an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60. In some [embodimentexamples](#), the antibody comprises: (a) heavy chain variable region comprising: (1) an HC-FR1 comprising the amino acid sequence of SEQ ID NO:26; (2) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61; (3) an HC-FR2 comprising the

amino acid sequence of SEQ ID NO:34; (4) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62; (5) an HC-FR3 comprising the amino acid sequence of SEQ ID NO:38; (6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and (7) an HC-FR4 comprising the amino acid sequence of SEQ ID NOs:45; and/or (b) a light chain variable region comprising: (1) an LC-FR1 comprising the amino acid sequence of SEQ ID NO:48; (2) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64; (3) an LC-FR2 comprising the amino acid sequence of SEQ ID NO:51; (4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65; (5) an LC-FR3 comprising the amino acid sequence of SEQ ID NO:55; (6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66; and (7) an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60. In some embodiment examples, the antibody comprises: (a) heavy chain variable region comprising: (1) an HC-FR1 comprising the amino acid sequence of SEQ ID NO:26; (2) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61; (3) an HC-FR2 comprising the amino acid sequence of SEQ ID NO:34; (4) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62; (5) an HC-FR3 comprising the amino acid sequence of SEQ ID NO:38; (6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63; and (7) an HC-FR4 comprising the amino acid sequence of SEQ ID NOs:45; and/or (b) a light chain variable region comprising: (1) an LC-FR1 comprising the amino acid sequence of SEQ ID NO:48; (2) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64; (3) an LC-FR2 comprising the amino acid sequence of SEQ ID NO:51; (4) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65; (5) an LC-FR3 comprising the amino acid sequence of SEQ ID NO:58; (6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66; and (7) an LC-FR4 comprising the amino acid sequence of SEQ ID NO:60. In some embodiment examples, the antibody comprises: a heavy chain variable region comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:88, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:91, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:94; and/or a light chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:97, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:100, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:103; a heavy chain variable region comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:89, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:92, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:95; and/or a light chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:98, (ii) HVR-L2 comprising the

amino acid sequence of SEQ ID NO:101, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:104; or a heavy chain variable region comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:90, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:93, and (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO:96; and/or a light chain variable region comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:99, (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:102, and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:105. In some [embodimentexamples](#), the antibody comprises: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:106; and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:109; a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:107; and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:110; or a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:108; and/or a light chain variable region comprising the amino acid sequence of SEQ ID NO:111. In some [embodimentexamples](#), the antibody binds to a human Siglec-8 and a non-human primate Siglec-8. In some [embodimentexamples](#), the non-human primate is a baboon. In some [embodimentexamples](#), the antibody binds to an epitope in Domain 1 of human Siglec-8, wherein Domain 1 comprises the amino acid sequence of SEQ ID NO:112. In some [embodimentexamples](#), the antibody binds to an epitope in Domain 3 of human Siglec-8, wherein Domain 3 comprises the amino acid sequence of SEQ ID NO:114. In some [embodimentexamples](#), the antibody binds to the same epitope as antibody 4F11. In some [embodimentexamples](#), the antibody binds to an epitope in Domain 2 or Domain 3 of human Siglec-8. In some [embodimentexamples](#), Domain 2 comprises the amino acid sequence of SEQ ID NO:113. In some [embodimentexamples](#), the antibody binds to the same epitope as antibody 1C3. In some [embodimentexamples](#), Domain 3 comprises the amino acid sequence of SEQ ID NO:114. In some [embodimentexamples](#), the antibody binds to the same epitope as antibody 1H10. In some [embodimentexamples](#), the antibody binds to an epitope in Domain 1 of human Siglec-8 and competes with antibody 4F11 for binding to Siglec-8. In some [embodimentexamples](#), the antibody does not compete with antibody 2E2 for binding to Siglec-8. In some [embodimentexamples](#), the antibody is not antibody 2E2. In some [embodimentexamples](#), Domain 1 comprises the amino acid sequence of SEQ ID NO:112. In some [embodimentexamples](#), the antibody is a human antibody, a humanized antibody, or a chimeric antibody. In some [embodimentexamples](#), the antibody comprises a heavy chain Fc region comprising a human IgG Fc region. In some [embodimentexamples](#), the human IgG Fc region comprises a human IgG1 Fc region. In some [embodimentexamples](#), the human IgG1 Fc region is non-fucosylated.

In some [embodimentexamples](#), the human IgG Fc region comprises a human IgG4 Fc region. In some [embodimentexamples](#), the human IgG4 Fc region comprises the amino acid substitution S228P, wherein the amino acid residues are numbered according to the EU index as in Kabat. In some [embodimentexamples](#), the antibody depletes blood eosinophils and/or inhibits mast cell activation. In some [embodimentexamples](#), the antibody has been engineered to improve antibody-dependent cell-mediated cytotoxicity (ADCC) activity. In some [embodimentexamples](#), the antibody comprises at least one amino acid substitution in the Fc region that improves ADCC activity. In some [embodimentexamples](#), at least one or two of the heavy chains of the antibody is non-fucosylated. In some [embodimentexamples](#), the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:75; and/or a light chain comprising the amino acid sequence selected from SEQ ID NO:76 or 77. In some [embodimentexamples](#), the antibody is lircatuzumab. In some [embodimentexamples](#), the antibody is a monoclonal antibody. In some [embodimentexamples](#), the composition comprises the antibody and a pharmaceutically acceptable carrier.

[0021] Further provided herein are kits or articles of manufacture comprising a medicament comprising a composition comprising an antibody that binds to human Siglec-8 and a package insert comprising instructions for administration of the medicament in an individual in need thereof according to any one of the above [embodimentexamples](#).

[0022] It is to be understood that one, some, or all of the properties of the various [embodimentexamples](#) described herein may be combined to form other [embodimentexamples](#) of the present disclosure. These and other [aspectexamples](#) of the present disclosure will become apparent to one of skill in the art. These and other [embodimentexamples](#) of the present disclosure are further described by the detailed description that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

[0023] **FIG. 1** shows that the primary endpoint of a Phase 2 study examining treatment of patients with EG and/or EGE using an anti-Siglec-8 antibody was met for all treatment groups.

[0024] **FIG. 2** shows that the total symptom score (TSS) secondary endpoint of the Phase 2 study was met for all treatment groups.

[0025] **FIG. 3** shows the improvement across all symptoms measured on treatment with anti-Siglec-8 antibody.